About this Research Topic
The management of colorectal cancer (CRC) has greatly benefited from the integration of several novel therapeutic approaches, ushering in a new era of personalized and effective treatment. Minimally invasive surgical techniques, such as laparoscopy and robotic-assisted surgery, have revolutionized surgical management. These techniques allow for smaller incisions, resulting in reduced postoperative pain, shorter hospital stays, and faster recovery times, which translate into an improved quality of life and a quicker return to daily activities.
In addition to surgical advancements, targeted therapy and immunotherapy have introduced a paradigm shift in CRC treatment. Targeted therapies leverage specific genetic mutations in cancer cells to provide a more precise attack compared to traditional chemotherapy, minimizing the side effects often associated with broad-spectrum drugs. For instance, drugs like cetuximab and panitumumab target the EGFR protein, a common mutation in some CRC cases. Immunotherapy, on the other hand, harnesses the body's own immune system to combat cancer. Checkpoint inhibitors such as pembrolizumab and nivolumab block proteins on cancer cells that normally suppress the immune response, enabling the immune system to recognize and attack cancer cells more effectively. Additionally, CAR T-cell therapy, a personalized approach, involves genetically engineering a patient's T cells to target specific cancer antigens, offering a promising new avenue for treatment.
We aim to comprehensively explore the transformative impact of novel therapeutic approaches in colorectal cancer (CRC) management, including minimally invasive surgery, targeted therapy, and immunotherapy. By analyzing their contributions to personalized treatment plans, patient outcomes, and survival rates, our goal is to provide valuable insights that encourage the wider adoption of these techniques, ultimately contributing to improved CRC treatment strategies.
This comprehensive analysis elucidates the transformative impact of novel therapeutic approaches on CRC management, offering valuable insights for oncologists, researchers, and policymakers. The integration of personalized, patient-centric benefits from these techniques can lead to the optimization of CRC treatment strategies.We welcome the articles including, but not limited to:
1.Personalized Treatment: Examining how minimally invasive surgery, targeted therapy, and immunotherapy enable personalized treatment plans, tailoring therapy to individual patient characteristics and tumor biology.
2.Improved Patient Outcomes: Investigating the impact of these novel techniques on patient outcomes, including reduced treatment-related morbidity, enhanced quality of life, and accelerated recovery times.
3.Enhanced Survival Rates: Exploring the potential of these advancements to improve survival rates in CRC patients, highlighting their contributions to extending life expectancy and reducing cancer mortality.
In addition to surgical advancements, targeted therapy and immunotherapy have introduced a paradigm shift in CRC treatment. Targeted therapies leverage specific genetic mutations in cancer cells to provide a more precise attack compared to traditional chemotherapy, minimizing the side effects often associated with broad-spectrum drugs. For instance, drugs like cetuximab and panitumumab target the EGFR protein, a common mutation in some CRC cases. Immunotherapy, on the other hand, harnesses the body's own immune system to combat cancer. Checkpoint inhibitors such as pembrolizumab and nivolumab block proteins on cancer cells that normally suppress the immune response, enabling the immune system to recognize and attack cancer cells more effectively. Additionally, CAR T-cell therapy, a personalized approach, involves genetically engineering a patient's T cells to target specific cancer antigens, offering a promising new avenue for treatment.
We aim to comprehensively explore the transformative impact of novel therapeutic approaches in colorectal cancer (CRC) management, including minimally invasive surgery, targeted therapy, and immunotherapy. By analyzing their contributions to personalized treatment plans, patient outcomes, and survival rates, our goal is to provide valuable insights that encourage the wider adoption of these techniques, ultimately contributing to improved CRC treatment strategies.
This comprehensive analysis elucidates the transformative impact of novel therapeutic approaches on CRC management, offering valuable insights for oncologists, researchers, and policymakers. The integration of personalized, patient-centric benefits from these techniques can lead to the optimization of CRC treatment strategies.We welcome the articles including, but not limited to:
1.Personalized Treatment: Examining how minimally invasive surgery, targeted therapy, and immunotherapy enable personalized treatment plans, tailoring therapy to individual patient characteristics and tumor biology.
2.Improved Patient Outcomes: Investigating the impact of these novel techniques on patient outcomes, including reduced treatment-related morbidity, enhanced quality of life, and accelerated recovery times.
3.Enhanced Survival Rates: Exploring the potential of these advancements to improve survival rates in CRC patients, highlighting their contributions to extending life expectancy and reducing cancer mortality.
Keywords: colorectal cancer, novel therapeutic approaches, minimally invasive, targeted, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
